Methylene blue as a vasopressor: a meta-analysis of randomised trials.

To evaluate the efficacy of methylene blue in raising mean arterial pressure in hypotensive patients. A meta-analysis of randomised controlled trials. We searched BioMedCentral, PubMed, Embase and the Cochrane Central Register of clinical trials. Inclusion criteria were random allocation to treatment and comparison of methylene blue versus any comparator. Exclusion criteria were duplicate publications, non-adult studies and no data on main outcomes. The primary end point was mean arterial blood pressure value 1 hour after the study drug administration; the secondary end points were mortality at the longest follow-up available, and cardiac index. Data from 174 patients in five randomised controlled studies were analysed. Mean arterial pressure rose in patients receiving methylene blue (weighted mean difference = 6.93 mmHg; 95% CI, 1.67 to 12.18; P for effect = 0.01; P for heterogeneity = 0.17; I2 = 41%). Only two studies reported the values of cardiac index with a non-statistically significant improvement in the methylene blue group (mean difference = 0.76 L/min/m2; 95% CI, ? 0.32 to 1.84; P for effect = 0.2). The overall mortality rate was 16% (14/88) among methylene blue treated patients and 23% (20/86) in the control group (odds ratio = 0.65; 95% CI, 0.21 to 2.08; P for effect = 0.5). Methylene blue increases arterial blood pressure and systemic vascular resistances in vasoplegic patients without a detrimental effect on survival.

Citation

Laura Pasin, Michele Umbrello, Teresa Greco, Massimo Zambon, Federico Pappalardo, Martina Crivellari, Giovanni Borghi, Andrea Morelli, Alberto Zangrillo, Giovanni Landoni. Methylene blue as a vasopressor: a meta-analysis of randomised trials. Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine. 2013 Mar;15(1):42-8

Mesh Tags

Substances

PMID: 23432501

search → result